Zynerba Archives

Debra BorchardtAugust 2, 2018

Zynerba Pharmaceuticals Inc. (ZYNE) reported a net loss of $12 million and a diluted net loss per share of $(0.89) for the second quarter ending June 30, 2018. General and administrative expenses were $3.4 million, including stock-based compensation expense of $1.0 million. Research and development expenses for the second quarter of 2018 were $8.5 million, including stock-based […]

Debra BorchardtJuly 5, 2018

It’s time for your Daily Hit of financial cannabis news for July 5, 2018. The markets were closed on Wednesday in honor of the Fourth of July. Because of the holiday, news has been fairly light this week and today was no exception. It feels like many companies either took the first two days of the […]

Debra BorchardtJuly 5, 2018

Cannabinoids drug company Zynerba Pharmaceuticals, Inc. (ZYNE) reported that the top-line results from a Phase 1 clinical program studying ZYN001 failed and that it will abandon the drug and instead focus on ZYN002. The shares fell over 20% in pre-market trading, but at the open fell 16% to lately trade at $8.01. The patent-protected, pro-drug of tetrahydrocannabinol (THC) was delivered via […]

Debra BorchardtMay 8, 2018

Beleaguered biotech company Insys Therapeutics Inc. (INSY) reported a loss of $20.4 million in the first quarter for a loss of $0.28 cents per share. Adjusted those losses ended up being $0.19 cents per share, meeting analyst expectations. The pharmaceutical company is known for its kickback scheme on painkillers still managed to post revenue of […]

StaffApril 25, 2018

Here’s your Daily Hit of cannabis financial news for April 25, 2018: On The Site: Zynerba Pharmaceuticals Inc. Zynerba Pharmaceuticals (ZYNE) announced 12-month results for its cannabidiol (CBD) gel to treat adults with epilepsy. The data is being presented today at the Emerging Science session of the 2018 Annual Meeting of the American Academy of Neurology (AAN) […]

Debra BorchardtApril 25, 2018

Zynerba Pharmaceuticals Inc. (ZYNE) announced 12-month results for its cannabidiol (CBD) gel to treat adults with epilepsy. The data is being presented today at the Emerging Science session of the 2018 Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, CA. The company is saying that the data show over the long […]

Debra BorchardtMarch 26, 2018

Clinical-stage pharmaceutical company Zynerba Pharmaceuticals (ZYNE) announced that researchers at The Scripps Research Institute and the University of Maryland have generated preclinical data from a study funded by NIH grants that suggest potential value in using its transdermal cannabidiol (CBD) (ZYN002) to reduce the risk of relapse among recovering drug and alcohol addicts. The study results […]

Debra BorchardtMarch 12, 2018

Cannabis-based biotech company Zynerba (ZYNE) reported fourth quarter and full-year results on Monday morning. The press release lead with drug study highlights versus financial information because it delivered a net loss of $8.1 million or 60 cents per share. Zynerba delivered a $32 million loss for 2017 versus a $23 million loss for 2016. There […]

William SumnerMarch 5, 2018

Zynerba Pharmaceuticals Inc. (ZYNE), a clinical-stage biopharmaceutical company dedicated to developing cannabinoid-based medicines, announced positive results from a meeting with the United States Food and Drug Administration (FDA). The stock initially popped on the news moving almost 5% higher to $10.50 before pulling back to $10.08 in midday trading. The meeting was in regards to […]

Debra BorchardtJanuary 30, 2018

Zynerba Pharmaceuticals Inc. (ZYNE) was initiated with a Buy rating and a $25.50 price target from analyst Michael Higgins at Ladenburg Thalman. Zynerba is a clinical-stage pharmaceutical company that focuses on using synthetic cannabinoid products in a transdermal delivery method. It has two main products ZYN002 and ZYN001, which are being tested for use in […]

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

In other news

The Daily Hit: January 4, 2024

Connecticut Attorney General Tells Unlicensed Cannabis Events Company to Stop

Testing Concerns Lead to Quarantine for 70% of Mississippi MMJ Goods

Tag: Zynerba

Zynerba Reports Loss As It Pushes Forward With ZYN002

The Daily Hit: July 5, 2018

Zynerba Test Fails, Shares Plunge Over 15%

Insys Therapeutics, Zynerba Both Report Q1 Losses

The Daily Hit: April 25, 2018

Zynerba Reports Seizure Reduction In Latest Study, But Placebo Results Are Absent

Addicts Could Get Help Staying Clean With Zynerba’s CBD Says New Study

Zynerba Delivers Losses For Fourth Quarter, Full Year

Zynerba Pharmaceuticals Stock Gets Early Pop On FDA Meeting

Zynerba Gets Buy Rating, $25.50 Target Price From Ladenburg Thalman

The Daily Hit - TEST TEST TEST

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

Get the latest cannabis news delivered right to your inbox

Get the latest cannabis news delivered right to your inbox